<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03336073</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-KyCyDex</org_study_id>
    <nct_id>NCT03336073</nct_id>
  </id_info>
  <brief_title>Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma</brief_title>
  <official_title>Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, phase II randomized controlled study that will evaluate
      the efficacy of carfilzomib and dexamethasone in combination with cyclophosphamide in R/R MM
      patients.

      For this purpose, R/R MM patients that have received 1-3 prior lines of therapy, and who are
      not primary refractory or refractory to proteasome inhibitors will be randomized to receive:

        -  Experimental arm: carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first
           infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose
           of 20 mg (10 mg for patients &gt;75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide
           at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles; or

        -  Control arm: the same treatment but without cyclophosphamide. Patients older than 75
           years will receive in both arms carfilzomib at a dose of 56 mg/m2 (20 mg/m2 only in the
           first infusion) during the cycles 1 and 2.

      If tolerability is acceptable, the dose could be increased up to 70 mg/m2 since the cycle 3.

      Treatment will be continued until progression, unacceptable toxicity or investigator or
      patient decision.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment will consist of 28-days cycles with:

        -  Arm 1 (experimental arm):

             -  Carfilzomib administered iv at a dose of 70 mg/m2 (20 mg/m2 only in the first
                infusion) iv on days 1, 8 and 15.

             -  Dexamethasone at a dose of 20 mg po (10 mg for patients &gt;75 years) days 1, 2, 8, 9,
                15 and 16.

             -  Cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15

        -  Arm 2 (control arm):

             -  Carfilzomib administered iv at a dose of 70 mg/m2 (20 mg/m2 only in the first
                infusion) iv on days 1, 8, and 15.

             -  Dexamethasone at a dose of 20 mg po (10 mg for patients &gt;75 years) days 1, 2, 8, 9,
                15 and 16.

      Patients older than 75 years will receive in both arms carfilzomib at a dose of 56 mg/m2 (20
      mg/m2 only in the first infusion) during the cycles 1 and 2.

      If tolerability is acceptable, the dose could be increased up to 70 mg/m2 since the cycle 3.

      Treatments will be administered until progressive disease (PD) or unacceptable toxicity.
      Carfilzomib and cyclophosphamide will be provided by the sponsor. Dexamethasone may be
      utilized per a site's standard practice and will not be provided by the sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of carfilzomib, dexamethasone and cyclophosphamide in number of responses obtiened</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluate the efficacy of carfilzomib and dexamethasone in combination with cyclophosphamide in terms of response rate in multiple myeloma (MM) patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of carfilzomib, dexamethasone and cyclophosphamide in Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>2 years</time_frame>
    <description>the safety as determined by the incidence of clinical and laboratory toxicities</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>carfilzomib, dexamethasone and cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients &gt;75 years) days 1, 2, 8, 9, 15 and 16 and cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15, in 28 days cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>carfilzomib and dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15, dexamethasone by mouth (po) at a dose of 20 mg (10 mg for patients &gt;75 years) days 1, 2, 8, 9, 15 and 16 , in 28 days cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <description>carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15</description>
    <arm_group_label>carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>carfilzomib, dexamethasone and cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>dexamethasone oral at a dose of 20 mg (10 mg for patients &gt;75 years) days 1, 2, 8, 9, 15 and 16</description>
    <arm_group_label>carfilzomib and dexamethasone</arm_group_label>
    <arm_group_label>carfilzomib, dexamethasone and cyclophosphamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15</description>
    <arm_group_label>carfilzomib, dexamethasone and cyclophosphamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary refractory patients defined as not having achieved at least a partial response
             with a prior therapy.

          -  Refractoriness to prior proteasome inhibitor therapies, defined as not having achieved
             at least MR or having progressed under treatment or in the first 60 days after the
             last dose of the proteasome inhibitor.

          -  Adequate haematological or biochemical parameters as specified below:

               -  Hemoglobin &lt;8.0 g/dL.

               -  Platelets count &lt;75x109/L without previous platelet transfusions in the last 7
                  days. If high bone marrow infiltration (&gt;50%) is present, ≥50x109/L platelet
                  count is required.

               -  Absolute neutrophil count (ANC) &lt;0.75 x109/L without previous G-CSF support in
                  the last 7 days.

               -  Aspartate transaminase (AST): &gt;2.5 x the upper limit range.

               -  Alanine transaminase (ALT): &gt;2.5 x the upper limit range.

               -  Total bilirubin: &gt;2 x the upper limit range.

               -  Calculated or measured creatinine clearance: &lt;30 mL/min (calculated from the
                  Cockcroft and Gault formula)

        Exclusion Criteria:

          -  Left ventricular ejection fraction &lt;50%.

          -  Absence of recovery from any significant non-haematological toxicity derived from
             previous treatments. The presence of alopecia and NCI-CTC grade &lt; 2 symptomatic
             peripheral neuropathy is allowed.

          -  Pregnant or lactating women; men and women of reproductive potential who are not using
             effective contraceptive methods (double barrier method, intrauterine device, oral
             contraception).

          -  Previous history of any other neoplastic disease in the last five years (except basal
             cell carcinoma, skin epithelioma or carcinoma in situ of any site).

          -  Other relevant diseases or adverse clinical conditions: Congestive heart failure or
             angina pectoris, myocardial infarction within 12 months before inclusion in the study;
             Uncontrolled arterial hypertension or cardiac arrhythmias (i.e. requiring a change in
             medication within the last 3 months or a hospital admission within the past 6 months);
             History of significant neurological or psychiatric disorders; Active infection;
             Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic hepatitis);

          -  Patient is known to be human immunodeficiency virus (HIV) positive, hepatitis B
             surface antigen-positive or to suffer active hepatitis C infection.

          -  Concomitant anti-myeloma therapy within 14 days prior to Day 1 of Cycle 1.

          -  Limitation of the patient's ability to comply with the treatment or follow-up
             protocol.

          -  Uncontrolled endocrine diseases (e.g. diabetes mellitus, hypothyroidism or
             hyperthyroidism) (i.e. requiring relevant changes in medication within the last month,
             or hospital admission within the last 3 months).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>M Victoria Mateos, Dr</last_name>
    <phone>34 923 29 16 34</phone>
    <email>mvmateos@usal.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrique M Ocio, Dr</last_name>
    <phone>34 923 29 16 34</phone>
    <email>emocio@usal.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Tenerife</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hernández Miguel, Dr</last_name>
      <phone>+ 34 922 67 80 00</phone>
    </contact>
    <investigator>
      <last_name>Hernández Miguel, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H.Universitari Germans Trias I Pujol de Badalona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Oriol, Dr</last_name>
      <email>aoriol@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Rosiñol, Dr</last_name>
      <phone>+ 34 93 2275400</phone>
      <email>LROSINOL@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Granell Gorrochategui, Dr</last_name>
      <phone>+ 34 93 5565647</phone>
      <email>MGranell@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ico L'Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sureda, Dr</last_name>
      <email>asureda@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Cáceres</name>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Carmen Cabrera, Dr</last_name>
      <phone>927 25 62 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Cabueñes</name>
      <address>
        <city>Gijón</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Esther González García</last_name>
      <phone>+ 34 985 18 50 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalario Universitario de Granada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Ríos Tamayo, Dr</last_name>
      <phone>+ 34 958 02 00 00</phone>
      <email>rafael.rios.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Escalante Barrigón, Dr</last_name>
      <phone>+ 34 987 23 74 00</phone>
      <email>fescalanteb@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Jose Lahuerta, Dr</last_name>
      <phone>+ 34 913 90 80 00</phone>
      <email>jjlahuerta@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>H. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Jesús Blanchard Rodríguez, Dr</last_name>
      <phone>+ 34 913 36 80 00</phone>
      <email>mjesusblanchard@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Pérez de Oteyza, Dr</last_name>
      <phone>+ 34 902 08 98 00</phone>
      <email>jperezoteyza@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe De Arriba, Dr</last_name>
      <phone>+ 34 968 36 09 00</phone>
      <email>Farriba@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgn de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José Moreno Belmonte, Dr</last_name>
      <phone>+ 34 968 36 95 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Casanova Espinosa, Dr</last_name>
      <phone>+ 34 951 97 66 69</phone>
      <email>mariacasanova@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Pilar González Rodríguez, Dr</last_name>
      <phone>+34 985 108 000</phone>
      <email>anapilargonzalez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Son Llàtzer</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Bargay, Dr</last_name>
      <phone>+ 34 871 20 20 00</phone>
      <email>jbargay@hsll.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Rodríguez Otero, Dr</last_name>
      <phone>+ 34 948 25 54 00</phone>
      <email>paurodriguez@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoapital Clinico Universitario Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Victoria Mateos, Dr</last_name>
      <phone>+ 34 923 29 11 00</phone>
      <email>mvmateos@usal.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Sonia González Pérez</last_name>
      <phone>+ 34 981 95 00 00</phone>
      <email>marta.sonia.gonzalez.perez@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Segovia</name>
      <address>
        <city>Segovia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aránzazu García Mateo, Dr</last_name>
      <phone>+ 34 921 41 91 00</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Martín, Dr</last_name>
      <email>jesusms79@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Toledo</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Felipe Casado Montero, Dr</last_name>
      <phone>+ 34 925 25 93 50</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Dourdil Sahun, Dr</last_name>
      <phone>+ 34 976 76 57 00</phone>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 25, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2017</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

